Sort
10,766 grants matching “checkpoint inhibitor”
Identification of Druggable Targets to Complement Melanoma Therapy
$358,700Alan Jackson Tackett · Univ Of Arkansas For Med Scis · R01 · FY2019 · CA
Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments that Include Immune Checkpoint Inhibitors and Targeted Therapy
$358,680Goldy C George · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
Define redundant functions of H2AX and NBS1 in DNA repair
$358,680Junjie Chen · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
53BP1-dependent pathway in DNA repair
$358,680Junjie Chen · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
Development of Long non-coding RNA-directed Target Therapy for Triple-Negative Breast Cancer
$358,680Chunru Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
Development of Long non-coding RNA-directed Target Therapy for Triple-Negative Breast Cancer
$358,680Chunru Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Vista, A Novel Checkpoint that Suppresses Anti-Tumor T Cell Responses
$358,678Li Lily Wang · Cleveland Clinic Lerner Com-Cwru · R01 · FY2019 · CA
Structural studies of molecular cancer targets and drug development
$358,538David S Waugh · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
DEREGULATION OF CELLULAR IKB KINASES BY HTLV1 TAX
$358,519Vanderbilt University · R01 · FY2000 · CA
Control of Cell Fate and Proliferation in the Developing Eye
$358,509Utpal Banerjee · University Of California Los Angeles · R01 · FY2011 · EY
Immunotherapeutic Modalities for K-ras Mutant Lung Cancer: Sex- and Cell Type-Specific Roles of IL-6/STAT3 signaling
$358,434Seyed Javad Mirhassani Moghaddam · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
DNA damage signaling to immune checkpoints
$358,311Christopher J. Bakkenist · University Of Pittsburgh At Pittsburgh · R01 · FY2020 · CA
Project 3: Development of Novel Therapies and Biomarkers for TNBC Patients
$358,272Charles M Perou · Univ Of North Carolina Chapel Hill · P50 · FY2024 · CA
Regulation of p53 by TAF1
$358,233Xuan Liu · University Of California Riverside · R01 · FY2019 · CA
Small molecule inhibitors as a new approach to study human RAD51 recombinase
$358,092Alexander V Mazin · Drexel University · R01 · FY2019 · CA
Checkpoints of TNF Gene Regulation
$358,071Anne Goldfeld · Boston Children'S Hospital · R01 · FY2013 · GM
Role of Sirt2 in T Cell Metabolism
$357,994Sungjune Kim · Mayo Clinic Jacksonville · R37 · FY2025 · CA
Robust-to-fragile transitions of a phase-separated mitotic organelle in triple-negative breast cancer
$357,982P. Todd Stukenberg · University Of Virginia · U54 · FY2023 · CA
Bile acids restrict functional reprogramming of myeloid-derived suppressor cells in tumor beds
$357,915Paulo Cesar Rodriguez · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2024 · CA
Characterizing oncogenic function of ITCH in melanoma
$357,913Lixin Wan · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2025 · CA
Impact of CREB-driven mechanism in shaping the tumor-immune landscape
$357,796Nagaraj S. Nagathihalli · University Of Miami School Of Medicine · R01 · FY2025 · CA
Reprogramming of the stromal microenvironment in melanoma progression and therapeutic escape
$357,712Yuhang Zhang · University Of Cincinnati · R01 · FY2022 · CA
Impact of Host NF-kB Signaling in Radiation Therapy
$357,634Shigeki Miyamoto · University Of Wisconsin-Madison · R01 · FY2024 · CA
Reprogramming the Tumor Microenvironment in Pancreas Cancer to Enhance Immunotherapy
$357,535Nipun B. Merchant · University Of Miami School Of Medicine · R01 · FY2018 · CA
Transformation by the NEU Oncogene Product and EGF
$357,470David F Stern · Yale University · R01 · FY2009 · CA